Creating molecules that can target and destroy cancer proteins
Official title: Evolved Molecules that Destroy Cancer Relevant Proteins
Funded at Foundation for Applied Molecular Evolutn · NIH-10916087 · Data updated 2026-11-12
This study is working on new tools that can help target and break down proteins related to cancer, with the goal of making cancer treatments faster and more affordable for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Foundation for Applied Molecular Evolutn NIH-funded |
| Lab location | 1 site (Alachua, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $215,564 |
| NIH project number | 1R61CA291117-01 |
| Project ID | NIH-10916087 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cancers that express specific proteins targeted by the AEGIS technology, such as breast or liver cancer.
✕Less likely to help
Patients with cancers that do not express the targeted proteins or those who are not eligible for experimental treatments may not benefit from this research.
What this research studies
This research focuses on developing innovative molecules called AEGISbodies and AEGISCleavers that can bind to and cleave cancer-relevant proteins. By utilizing a unique laboratory evolution technique, the researchers aim to produce these molecules at a significantly lower cost and faster pace than traditional methods. The approach involves using an artificially expanded genetic information system to create highly stable and functional biopolymers that can specifically target cancer cells. Patients may benefit from the advancements in cancer treatment that these new reagents could facilitate.
Why it matters
Potential benefit: If successful, this research could lead to more effective and affordable cancer treatments by targeting and destroying specific cancer proteins.
How similar studies have gone: Other research has shown promise in using similar molecular targeting approaches in cancer treatment, indicating potential for success in this novel application.
Where this research is happening
-
Foundation for Applied Molecular Evolutn
Alachua, United States Active
Researchers
- Principal investigator: Biondi, Elisa — Foundation for Applied Molecular Evolutn
- Study coordinator: Biondi, Elisa
Related research
Other NIH-funded projects on the same topics.
-
Tau and p-Tau blood biomarkers to predict outcomes after complicated mild traumatic brain injury
A research team is validating Tau and phosphorylated Tau as blood biomarkers to help predict which patients with complicated mild TBI will have poorer outcomes.
-
Custom molecules that destroy cancer proteins
Researchers are building synthetic molecules that stick to and cut cancer-related proteins to speed up cancer research and future treatments.
-
Improving COVID-19 diagnostics in low-resource settings
This study is looking at how DNA and RNA work together to make better tests for COVID-19 and other germs, so that patients can get quicker and more accurate results, especially in places that might not have a lot of resources.
-
Creating stable antibody replacements on demand
This study is exploring a new kind of antibody replacement called Spiegel ERAbodies, which can be made quickly and easily to help scientists better understand diseases and improve treatments, making the process faster and more affordable.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.